Innoviva (INVA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Mar, 2026Executive summary
The annual meeting is scheduled for May 4, 2026, with voting on four key proposals: election of five directors, advisory vote on executive compensation, ratification of Deloitte & Touche LLP as auditor, and approval of the 2026 Equity Incentive Plan.
Shareholders of record as of March 9, 2026, are eligible to vote in person, by mail, phone, or internet.
The Board recommends voting in favor of all proposals and has provided detailed proxy materials and voting instructions.
Voting matters and shareholder proposals
Proposal 1: Elect five directors for a one-year term; all nominees are current directors and recommended by the Board.
Proposal 2: Advisory (non-binding) vote to approve executive compensation (Say-on-Pay).
Proposal 3: Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026.
Proposal 4: Approval of the 2026 Equity Incentive Plan, reserving 9,000,000 shares for issuance.
No other shareholder nominations for directors were received; deadlines for 2027 proposals are specified.
Board of directors and corporate governance
The Board consists of five directors, with a majority deemed independent under Nasdaq standards.
Board committees: Audit, Compensation, and Nominating/Corporate Governance, all comprised of independent directors.
Chairperson and CEO roles are separated; Mark A. DiPaolo serves as independent Chair.
Directors are subject to majority voting in uncontested elections and must tender conditional resignations if not re-elected.
Stockholder communications and director nomination procedures are established.
Latest events from Innoviva
- Q2 2026 revenue rose 19% but a $161M investment loss led to an $83.4M net loss.INVA
Q2 2026 - Strong royalty streams and specialty therapeutics drive growth and global expansion prospects.INVA
H.C. Wainwright 26th Annual Global Investment Conference 2024 - Three-pillar model drives growth and stability, with IST and strategic assets fueling future value.INVA
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Q1 2026 saw 11% revenue growth, robust net income, and major gains in equity investments.INVA
Q1 2026 - Strong growth, new product launches, and major clinical milestones set for 2026.INVA
Oppenheimer 36th Annual Healthcare Life Sciences Conference - Strong 2025 growth fueled by resilient royalties, specialty therapeutics, and strategic investments.INVA
Corporate presentation - 2025 revenue rose 15% to $411.3M, with net income of $271.2M and strong IST sales growth.INVA
Q4 2025 - Growth driven by hospital therapeutics, strategic assets, and key product launches ahead.INVA
2024 Cantor Fitzgerald Global Healthcare Conference - Transitioning to a commercial-stage leader in hospital and infectious disease, with strong growth and profit focus.INVA
Goldman Sachs 45th Annual Global Healthcare Conference